Iyizoba-Ebozue Zsuzsanna, Burton Cathy, Prestwich Robin J D
Department of Clinical Oncology, Leeds Cancer Centre, Leeds, UK.
Haematology Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
Clin Transl Radiat Oncol. 2020 Jan 22;21:66-68. doi: 10.1016/j.ctro.2020.01.002. eCollection 2020 Mar.
Histiocytic sarcoma (HS) is an exceedingly rare and aggressive neoplasm of lymphoid and haematopoietic tissues and expresses histological and phenotypical characteristics of mature histiocytes. There have only been a few cases of documented HS in the head and neck region. Whilst patients with HS often have nodal or disseminated disease, patients can present with localised disease. There are currently no established treatment guidelines, and reported cases of localised disease have been managed with primary surgery and adjuvant radiotherapy and/or chemotherapy. Here we present, the case of a 49 year old man with a HS of the base of tongue treated with radical radiotherapy to a dose of 60 Gy in 30 fractions, achieving disease free survival of greater than 5 years with minimal toxicity. To our knowledge, this is the first reported case of HS treated with radical radiotherapy, and suggests that when the potential morbidity of surgery for localised disease is significant, radiotherapy may represent an alternative treatment.
组织细胞肉瘤（HS）是一种极其罕见且侵袭性的淋巴和造血组织肿瘤，具有成熟组织细胞的组织学和表型特征。头颈部区域仅有少数记录在案的HS病例。虽然HS患者常出现淋巴结或播散性疾病，但也可表现为局限性疾病。目前尚无既定的治疗指南，已报道的局限性疾病病例采用了原发手术及辅助放疗和/或化疗进行治疗。在此，我们报告一例49岁男性舌根部HS患者，接受了30次分割、总剂量60 Gy的根治性放疗，以最小的毒性实现了超过5年的无病生存。据我们所知，这是首例报道的采用根治性放疗治疗HS的病例，表明当局限性疾病手术的潜在发病率较高时，放疗可能是一种替代治疗方法。
